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Introduction
Cervical cancer is still the second most common cancer among women worldwide although efforts have been made for early detection and treatment. It causes half a million deaths each year. 1 These facts highlight the importance of developing efficient treatment approaches for this disease. Because of the strong relationship between human papillomavirus (HPV) infection and cervical cancer, 2 methods targeting to HPV oncogene expression will likely generate treatment modalities for cervical cancer. Down-regulation of oncogene expression using antisense-based gene therapy or antisense oligonucleotide in certain types of malignant tumors, including cervical cancer, has been actively studied and therapeutic effects have been demonstrated in some animal tumor models. 3, 4 We recently showed that a strong antisense RNA expression promoter, U6 snRNA promoter, could produce a large amount of U6/E6 or U6/E7 antisense chimeric RNA which resulted in significant tumor growth inhibition and regression if the tumors were small. 5 However, the in vivo transfection efficiency of liposome-DNA complex is low as demonstrated by X-gal staining. 6 Nevertheless, complete tumor regression had been observed in the syngeneic mouse model. 5 This suggests that other mechanisms may be involved in addition to the direct down-regulation of E7 oncogene expression by the antisense effect of E7 antisense RNA (E7AS). Since this experiment was done in syngeneic mice, one possibility is that antisense-induced cell death triggered the host antitumor immune response which then eliminated the tumor.
Another widely studied cancer treatment approach is the cytokine-mediated cancer gene therapy. It is well established that some cytokines such as interleukin 2 (IL-2) and interleukin (IL-12) can enhance the host immune response against cancer. 7, 8 We hypothesize that E7AS might elicit a host antitumor immune response and this antitumor immunity might be potentiated by the action of IL-12 gene. In the current study, we tested this antisense-induced antitumor immune response hypothesis. We found that E7AS could induce tumor cell apoptosis and a host antitumor immune response which eliminated small size tumors. Moreover, this antisense-induced antitumor effect was significantly enhanced by co-delivery of IL-12 gene.
Results
Gene expression after intratumoral injection of DCChol/plasmid DNA complex lasted for about a week although only a small number of cells were transfected In order to measure the level and the duration of gene expression after intratumoral injection of liposome-plasmid DNA complex, 50 g of the plasmid pCMV-Luc DNA complexed with DC-Chol liposome were injected into each tumor (four tumors at each time-point). Tumor tissues were collected and homogenized and the luciferase activity was measured. The results showed that gene expression achieved a relatively high level 2 days after injection which lasted for about a week (Figure 1a) . The amount of luciferase protein was calculated based on the standard curve used in this laboratory (1 × 10 6 RLU/ng luciferase protein).
9 Approximately 2-5 ng of luciferase protein was detected on day 2 after injection in each tumor which was about 100 mg in mass. In order to determine the in vivo transfection efficiency after intratumoral injection of liposome-DNA complex, 50 g of pCMV-lacZ DNA was complexed with 50 nmol of DCChol and injected into tumors. Two days later, the tumor was sectioned and stained with X-gal. Approximately 1% tumor cells was strongly positive, while there were some weakly stained cells (data not shown). This level of transfection efficiency is comparable to a previous report. 6 IL-12 gene was highly expressed in cultured cells and in tumor The mouse IL-12 (mIL-12) gene was inserted into pCMVA vector under the control of the CMV promoter. In a preliminary experiment, we detected high level expression of mIL-12 in cultured cells that were either transiently transfected (up to 3 ng/10 6 cells/24 h) or stably transfected (up to 40 ng/10 6 cells/24 h) with the pCMVmIL-12 plasmid. mIL-12 expression was also detected after intratumoral injection by ELISA assay. The amount of IL-12 in the tumor was in the range of 100 pg to 200 pg per tumor (Figure 1b) . Since the tumor volume was about 0.2 ml, the concentration of IL-12 in the tumor was about 0.5-1 ng/ml. It has been reported that 30 pg/ml of IL-12 in the tumor could delay the tumor growth. 10 The amount of IL-12 produced in the tumor was much higher than the local amount required to delay tumor growth. However, there was no detectable IL-12 in the mouse serum (Figure 1b) .
Apoptosis was induced in E7AS-and IL-12-treated tumors
In order to determine the antisense-induced apoptosis, tumors were collected after three injections (10 days from the first injection). Tumor sections were stained with ApopTag kit and the data were analyzed by computer. As shown in Figure 2 , tumor cell apoptosis was demonstrated in E7AS-treated tumors at 61 ± 7 apoptotic cells per field (n = 3), whereas little apoptosis occurred in the E7S-(9 ± 2 cells per field) or pCMVA vector controltreated tumors (9.6 ± 1.5 cells per field). Significant amounts of apoptotic tumor cells were also demonstrated in pCMVmIL-12 (61 ± 10 cells per field) and pU6E7AS+pCMVmIL-12-treated tumors (77 ± 8 cells per field). However, there was little increase in terms of the number of apoptotic cells in the pU6E7AS+pCMVmIL-12-treated group in comparison with the pU6E7AS (P = 0.061) or pCMVmIL-12 alone (P = 0.116) treated groups. This might be related to the doses used in the treatment. Only half of the dose (25 g) of the pU6E7AS and pCMVmIL-12 was used in the combination group, while the full dose (50 g) was used in the pU6E7AS or pCMVmIL-12 alone treated tumors. In order to test if apoptosis could be induced in cultured cells, C3 cells were transfected with pU6E7AS. Three days later, cells were stained with ApopTag kit. As shown in Figure 3 , apoptosis was detected in pU6E7AS-treated C3 cells at 10.7 ± 3.5 apoptotic cells per field (n = 3). Compared with E7AS, E7S induced less apoptosis in cultured C3 cells at 4.3 ± 2.1 apoptotic cells per field (n = 3, P = 0.027). In terms of the number of apoptotic cells per field, there was only a nominal increase in the pU6E7AS-treated cells compared with the pU6E7S-treated cells. However, due to the growth inhibition induced by E7AS, the cell density of pU6E7AS-treated plates was lower (right panel in Figure 3 ). The percentage of apoptosis in pU6E7AS- treated cells was significantly higher than in pU6E7S-treated cells (4.6 ± 1.1% versus 1.5 ± 0.5%, P = 0.005).
Tumor growth inhibition and regression after intratumoral injection of the plasmids pU6E7AS or pCMVmIL-12 One of the main objectives of this study was to test whether the combination of IL-12 and E7AS could additively or even synergistically inhibit and eliminate established tumors in a syngeneic mouse model. For this purpose, six experimental groups were included. As shown in Figure 4 and Table 1 , the pU6E7AS plasmid can inhibit tumor growth and induce tumor regression. About 38% of the pU6E7AS-treated tumors completely regressed at the end of the experiment and 13% of the tumors had partial response of tumor growth inhibition or partial regression. However, these tumors rapidly grew back when the injection was discontinued. In the pCMVmIL-12 treatment group, about 50% of the tumors completely regressed, only one tumor in this group was growth inhibited, the other 46% of tumors continued to grow. The tumor size in the tumor-bearing mice from the pCMVmIL-12-treated group was not significantly different from that of the control group. However, the growth inhibition and regression were greatly pronounced in the group treated with pU6E7AS+pCMVmIL-12. Tumor growth was inhibited from the beginning in this treatment group and tumor regression was observed in the majority of tumors 1-2 weeks after treatment cessation. Complete tumor regression was observed in 93% (26/28) of the tumors and partial response was noticed in one tumor in the pU6E7AS+pCMVmIL-12 gene treatment group. In contrast, the antitumor effect in the pU6E7S+pCMVmIL-12 combination treatment group is similar to that in the pCMVmIL-12 alone treatment group. Forty-four per cent (8/18) of the tumors in the pU6E7S+pCMVmIL-12-treated group completely regressed. In the empty vector (pCMVA) control group there was no tumor growth inhibition and regression. The sense plasmid control also showed some therapeutic effect (20%) as we previously reported. 5 Antitumor effect was systemic Since the antisense and IL-12-induced tumor regression might be at least partially mediated through the syngeneic host immune system, we tested whether the intratumoral injection elicited systemic antitumor effect. C3 tumor cells were inoculated on both sides (left and right, 1 cm apart from each other) of the abdomen, and injection of pU6E7AS+pCMVmIL-12 was performed on the left side tumor only. In group A, 1 million C3 cells were inoculated on each side of the abdomen, while in group 
Figure 4 C3 tumor growth inhibition and regression by E7AS and IL-12 genes. This is a typical result of five individual experiments. Each group contained five mice (except that the pU6E7S+pCMVmIL-12 group contained eight mice). Numbers in parentheses indicate the number of tumorbearing mice out of five mice at the end of experiment. Arrows indicate the time of injection.
B, 1 million C3 cells were inoculated on the left side and 0.5 million C3 cells were inoculated on the right side. As shown in Table 2 , after six injections in 3 weeks and 2 more weeks without injection, eight of 10 tumors on the left side in group A and all 10 tumors on the left side in group B completely regressed. Of the eight mice whose tumors regressed in group A, four tumors (50%) on the right side completely regressed. In contrast, eight of 10 tumors (80%) on the right side in group B completely regressed. These results indicated that antisense and IL-12-induced antitumor effect can eradicate established tumor at another location. Furthermore, these data suggest that tumor regression mediated by host immune response is tumor burden dependent.
Immunity against the C3 tumor was generated in tumorfree mice In order to study whether antitumor immunity was developed in the tumor-free mice, 20 such tumor-free mice from different treatment groups (six from pU6E7AS, six from pCMVmIL-12, six from pU6E7AS+pCMVmIL-12 and two from pU6E7S) were rechallenged with fresh tumor cells. Ten tumor-bearing mice and 10 naive mice were also included in this experiment. One million C3 cells were inoculated on the opposite side of the abdomen 1 month after the tumor had regressed. As summarized in Table 3 , tumors were observed in only two of 20 Injection was performed twice a week for 3 weeks. Two weeks later, data were collected and summarized as below. CR (complete response), tumors completely regressed and did not return for at least 2 more months; PR (partial response), tumors did not grow or partially regressed during the 3-week treatment period but were not eliminated and eventually grew back when the injection was discontinued; NR (no response), tumor growth and size were not different from the tumor in the pCMVA control group; ND, experiment was not done. Two tumors were established in the abdomen of each mouse and were separated from each other by 1 cm. Injections were performed twice a week for 3 weeks only on the left tumors. Two weeks later, the results were collected and summarized in the table. a Four tumors on the right side of the mice whose left tumor regressed. a These tumors grew slower and the size was smaller than the tumors from naive mice and the tumor-bearing mice.
mice upon this second challenge. However, naive mice and tumor-bearing mice did not have the immunity against C3 cell challenge and tumors were established in all mice. Only two mice were not completely immunized against the C3 cell rechallenge, however, tumor growth was slow and the tumor size was small. These two mice were from the pU6E7S-treated group which were also tumor free when we started rechallenging with C3 cells. In order to demonstrate that the antitumor immunity is C3 specific, 10 tumor-free mice from the pU6E7AS+pCMVmIL-12-treated group were rechallenged with one million C3 on the left side and one million BL/6 cells on the right side of the abdomen. Although there were no C3 tumors established 1 month later, BL/6 tumors grew in nine of 10 mice. However, a delay in tumor establishment was noticed. In naive mice, tumors become palpable 3 days after inoculation with one million BL/6 cells. In the C3 tumor-free mice, BL/6 tumors did not become palpable until 8 days later.
CTL activity was generated in mice with complete tumor regression It has been shown before that cytokine-induced antitumor effect is associated with CTL activity. 11 To assay for the primary CTL activity, splenocytes from the tumorfree and naive mice were isolated and incubated with 51 Cr-labeled C3 target cells. However, we did not obtain a significant increase of CTL activity in comparison with the splenocytes from naive mice (data not shown). To determine whether secondary CTL activity can be detected, spleen T lymphocytes were isolated and incubated with mitomycin C-treated C3 cells for 5 days and CTL activity was then measured. Splenocytes from the tumor-free mice in all pU6E7AS, pCMVmIL-12, pU6E7AS+pCMVmIL-12-treated groups showed strong CTL activity ( Figure 5) . However, the CTL activity in the pU6E7AS+ pCMVmIL-12-treated mice was approximately 1.5-fold higher than in the pU6E7AS or pCMVmIL-12 alone treated mice. Approximately 45% (pU6E7AS+pCMVmIL-12 group) of the target cells were lysed at 50:1 (effector:target) ratio, whereas T lymphocytes from the naive mice had only resulted in 15% of the target cells lysis. In contrast, splenocytes from the pU6E7S-treated mice show no increased CTL activity against C3 target cells. There was no increased CTL activity against BL/6 tumor cells, indicating that the antitumor CTL activity was tumor specific ( Figure 5 ).
Figure 5 Target C3 cell lysis by CTL from tumor-free mice. CTL assay was performed as described in Materials and methods. Three tumor-free mice from each group were included. Cell lysis activity was measured for both C3 (a) and BL/6 (b) cells as a target.

CD8
+ and CD4 + lymphocyte infiltration to the tumor CD4 + and CD8 + cells were involved in the tumor regression after gene gun-mediated delivery of the IL12 gene. 11 To study the role of CTL in the pU6E7AS-induced regression, immunohistochemistry staining for the CD4 + and CD8 + T lymphocytes was performed. Tumors were collected and sectioned after three injections (10 days from the first injection). The slides were analyzed and scored by computer. As shown in Figure 6 , both CD8 + , 151 ± 15, P = 0.234). There was no T cell infiltration in the pCMVA vectortreated tumors ( Figure 6 ).
Discussion
Specific down-regulation of target gene expression which is involved in the process of neoplastic transformation and progression has been extensively studied. Antisense strategy is widely studied for inhibiting target gene expression since it theoretically possesses the potential of specificity and efficacy. However, most studies concentrated on the direct down-regulation of target gene expression and have assumed that down-regulation of the target gene expression is the direct cause of tumor growth inhibition. Little attention has been paid to the intermediate steps between target gene down-regulation and tumor growth inhibition. Two groups demonstrated that down-regulation of insulin-like growth factor gene expression in rat glioblastoma by antisense RNA resulted in an increase of MHC-1 and B-7 gene expression, which rendered the tumor cells more immunogenic and stimulated host antitumor immune response. [12] [13] [14] Alternatively, dead tumor cells themselves might be able to stimulate host immune system. Vile et al 15 recently demonstrated that HSVtk gene-transfected tumor cells killed by ganciclovir could stimulate the immune mononuclear cell infiltration into the tumor and Th1-like profile of intratumoral cytokine expression. These studies indicate that the host immune system is involved in cell death-induced antitumor effect.
We have previously shown that antisense RNA expression plasmids targeted to HPV16 E6 and E7 gene inhibited C3 tumor growth in syngeneic mouse, and in some cases, regressed the tumors completely. Since the liposome-DNA complex could not transfect all the tumor cells in vivo we propose that the host immune response could be involved, in addition to the direct tumor growth inhibition by E7AS. 5 The current study was designed to test this hypothesis and attempted to enhance the E7AS-induced antitumor effect by co-delivery of mIL-12 gene. As demonstrated in this study, E7AS induced tumor cell apoptosis. It is likely that the apoptotic tumor cells induced by E7AS triggered the host antitumor immune response because the control pU6E7S and pCMVA empty plasmid-treated tumors showed little cell apoptosis and no antitumor immune response ( Figures 3, 4 and 5, and Table 1 ). It is possible that antisense treatment alone induced cell death and the dead cells were then processed and presented by antigen presenting cells such as dendritic cells and macrophages. This hypothesis was justified by the latest work from Albert et al 16 which showed that dendritic cells can only process and acquire antigen from apoptotic cells and induce CTLs. This possibility is supported by the infiltration of CD4 + and CD8 + T lymphocyte in the tumors treated with pU6E7AS alone (Figure 6 ). Although we were unable to detect the increase of lymphocyte infiltration in the combinationtreated tumors, we did see higher CTL activity in the mice treated with both pU6E7AS+pCMVmIL-12 ( Figure  5 ). Although there is a small amount of CD8 + cell infiltration in the pU6E7S-treated tumors, these cells were mainly localized in the periphery of the tumor, which might explain the slight growth inhibition effect demonstrated in the pU6E7S-treated tumors. 5 However, the fact that there is no increased CTL activity from the pU6E7S-treated mice indicates that the infiltrated T lymphocytes might not function properly. Although both E7AS and IL-12 induced apoptosis (Figure 2 ), the mechanism might be different. Since the tumors were collected 10 days after first injection, there was tumor T lymphocyte infiltration ( Figure 6 ) which should cause tumor cell apoptosis. IL-12-induced apoptosis was likely mediated through the action of tumor infiltrated CTL. We were unable to distinguish between the direct effects and the immunemediated effects in the induction of apoptosis in this study. However, in a separate study, we demonstrated that a similar U6/EGFR antisense construct by itself could induce apoptosis of a xenografted human tumor in nude mice. 17 In addition, the data from in vitro transfection also demonstrated that E7AS could induce apoptosis although the major effect of E7AS on C3 tumor cells was growth inhibition (Figure 3 ). Based on these data, C3 tumor cell apoptosis after intratumoral injection of pU6E7AS may come from the combination of direct inhibition of HPV16 E7 gene expression by E7AS and infiltrated CTL. It would be interesting to study the tumor cell apoptosis, T cell infiltration and CTL activity at different time-points to understand the sequential order of the tumor cell death and host antitumor immunity.
The cytokine-mediated immunogene therapy has been developed as an experimental cancer treatment modality. IL-12 can exert a strong antitumor effect if sufficient dose is given systematically. However, toxicity is also increased and may result in some serious side-effects such as splenomegaly. Alternative approaches have been developed for IL-12-based cancer immunotherapy, such as the IL-12 gene-engineered fibroblast which produces IL-12 when implanted into the host. 18, 19 Several gene therapy approaches have been adopted to achieve efficient therapeutic activity with reduced toxicity. Such approaches include gene gun bombardment of the tumor, 11, 20 the use of adenoviral vector 21 and the injection of naked plasmid DNA. 22 In this study, we used a liposome vector to deliver the plasmid DNA to tumor cells by direct intratumoral injection. Liposomes have the merit of simplicity in preparation and use. They can also be used for multiple injection due to the lack of host immune response against the liposome. 23 Using luciferase reporter gene, we demonstrated that about 2-5 ng of luciferase protein was produced in each tumor 2 days after injection and that the expression lasted for at least a week. However, the in vivo transfection efficiency as demonstrated by the X-gal staining was relatively low. This might be due to low sensitivity of X-gal staining method which required about 3000 molecules of ␤-galactosidase in a cell. 24 Similarly, the IL-12 gene expression was also detected in the tumor to a lesser extent of about 150 pg. The fact that we were unable to detect IL-12 in the serum may indicate that systemic toxicity associated with this cytokine therapy is minimal. With a sufficient amount of IL-12 locally produced inside the tumor, significant antitumor effect was obtained by a combination treatment with the HPV16 E7AS expression plasmid. We found that almost all of the tumors were completely regressed (Table 1) . Although there was some variability in the pCMVmIL-12 or pU6E7AS alone treated group in different experiments, the therapeutic effect of the combination group was quite consistent and reproducible.
In our study, the IL-12 gene induced strong antitumor immune response, about 50% of the IL-12 gene-treated tumors completely regressed, and 4% of tumors had a partial response. This is comparable with the data obtained by gene gun or adenovirus-mediated IL-12 gene delivery. 11, 20, 21 As shown in Figure 4 and Table 1 , the antitumor activity of IL-12 and E7AS was additive, such that almost all tumors treated with the pU6E7AS+pCMVmIL-12 regressed. A simple explanation for these data is that while the E7 antisense RNA inhibits tumor growth (tumor cell arrest) or cell death, the host is developing an antitumor immune response which is augmented by IL-12. The host antitumor immunity and E7AS can eliminate small size tumors but not larger ones. If pCMVmIL-12 alone is used for the treatment of cancer, the tumor is still growing while the host is developing an immune response against the tumor. By the time the host has built the antitumor immune response, the tumor burden might be already too large for elimination. In contrast, if the injection included the pU6E7AS plasmid DNA, the tumor growth might be immediately inhibited by the E7AS so that the tumor size would not be too large to be eliminated when the host immune response is elicited 1 or 2 weeks later.
Although several studies had been performed using the combination of IL-12 protein and chemotherapeutic drugs, the results were not conclusive. Brunda et al 11 demonstrated that in combination with doxorubicin, IL-12 resulted in a greater antitumor efficacy, while other drugs did not show such enhancement. This might be related to the cytotoxicity of chemotherapeutic drugs which in most cases inhibit the host immune system by inhibiting cell proliferation. In contrast, antisenseinduced cell apoptosis is specific with no inhibition on the host immune system. Based on these advantages, a combination of antisense and cytokines should result in a significant additive antitumor effect. The results shown in this study justify this rationale. Several combination gene transfer approaches have been investigated in order to achieve a significant therapeutic effect against cancer. One study involved the using of HSVtk and IL-2 genes. 25 Another one examined a combination of p21 and H-2Kb genes. 26 In both cases, significant improvement of the therapeutic effect was obtained. The combined therapeutic modality might have a wide range of application in the treatment of different tumor models and may find its way into clinical application.
Materials and methods
Plasmid construction IL-12 expression plasmid (pCMVmIL-12) was constructed by cutting the mIL-12 two subunit genes into the pCMVA vector (Aurogene, WI, USA) in which the IL-12 gene expression is under the control of the CMV promoter. Plasmids pU6E7AS and pU6E7S were as described previously.
5 pCMV-Luc is the plasmid containing the firefly luciferase gene driven by the CMV early gene promoter in pcDNA3 (Invitrogen, Carlsbad, CA, USA).
Luciferase assay and X-gal staining Tumor tissue was homogenized in lysis buffer containing 0.05% Triton X-100, 100 mm Tris, pH 7.8 and 2 mm EDTA, supernatant was collected after centrifugation and luciferase activity measured using an Automated LB953 luminometer (Berthold, Bad Wildbad, Germany). X-gal staining of tumor sections were performed according to the method previously described. 6 Expression of IL-12 Expression of mIL-12 from the pCMVmIL-12 was measured using the cultured cells 2 days after transfection.
The culture supernatant was collected and ELISA was done to measure the amount of mIL-12. To check mIL-12 gene expression, the tumor was injected with 50 g pCMVmIL-12 DNA and 50 nmol DC-Chol liposome complex. Two days later, tumor tissues were dissected and homogenized in lysis buffer described above using a glass homogenizer. The supernatant was collected and ELISA was performed using the mIL-12 detection kit as described by the manufacturer (Genzyme, Cambridge, MA, USA).
Tumor inoculation C3 tumors were established as described before. 1 Briefly, C3 cells were trypsinized and washed three times with Hank's solution. One million of such C3 cells in 50 l were inoculated subcutaneously in the abdomen of C57BL/6 female mice which were purchased from Charles River Laboratories (Wilmington, MA, USA) and housed in accordance with institutional guidelines. Tumor size was monitored by measuring the two perpendicular dimensions before each injection. Tumor size was calculated by multiplying the two measured diameters. Tumors were normally established in 4 days and grew to the size of 3.5 × 3.5 to 4 × 4 mm in 1 week from injection.
Intratumoral injection
Fifty micrograms of plasmid DNA were complexed in 5% glucose isotonic solution with DC-Chol liposome which was prepared by microfluidization. 27 Fifty l of the liposome-DNA complexes were injected into the tumors intratumorally. Injection was performed twice a week and lasted for 3 weeks. Among five individual experiments, the last three experiments were performed double-blind.
Immunohistochemistry staining
The CD8
+ and CD4 + cells were stained by using the antibody against the CD8 and CD4 molecules. Briefly, tumor tissue was sectioned on the cryostat at 5 m and the slides were fixed in acetone. Slides were incubated with avidin blocker and followed by biotin blocker (Vectors Laboratories, Burlingame, CA, USA). Primary antibody, anti-CD4 or anti-CD8 (Pharmingen, San Diego, CA, USA) was applied and incubated for 1 h. After washing with PBS, biotin labeled-secondary antibody (Pharmingen, San Diego, CA, USA) was added to the slides and incubated for 30 min. After washing with PBS, ABC reagents (Vectors Laboratories) were applied. Slides were developed by using AEC (amine ethylcarbon) (Sigma, St Louis, MO, USA) solution and counterstained with hematoxylin (Sigma). Slides were observed under ×400 magnification for positive cells. The signals were analyzed by using the computer program IP LAB from Signal Analytic (Vienna, VA, USA).
CTL assay
Splenocytes were collected from mice and red blood cells were lysed by adding ddH 2 ) were used to measure the T cell lytic activity. The effector and target cells were incubated together for 4 h at 37°C. The supernatant was collected and radioactivity counted in a gamma counter. The percentage of lysis was calculated as previously described. 28 Apoptosis staining Tumors were collected after three injections before the tumors were completely regressed. Apoptosis staining was done using the ApopTag Kit as described by the manufacturer (Oncor, Gaithersburg, MD, USA). Slides were observed under ×200 magnification using FITC filter for the positive green cells. The signals were analyzed on computer using the IP LAB program (Signal Analytic). Apoptosis staining for cultured cells was also performed using the same kit according to the conditions recommended by the manufacturer.
